UPTRAVI is a Oral Tablet, Coated in the Human Prescription Drug category. It is labeled and distributed by Actelion Pharmaceuticals Us, Inc.. The primary component is Selexipag.
| Product ID | 66215-606_32a13445-38fd-4dcd-b2e1-e84b7c11d4b6 |
| NDC | 66215-606 |
| Product Type | Human Prescription Drug |
| Proprietary Name | UPTRAVI |
| Generic Name | Selexipag |
| Dosage Form | Tablet, Coated |
| Route of Administration | ORAL |
| Marketing Start Date | 2015-12-21 |
| Marketing Category | NDA / NDA |
| Application Number | NDA207947 |
| Labeler Name | Actelion Pharmaceuticals US, Inc. |
| Substance Name | SELEXIPAG |
| Active Ingredient Strength | 600 ug/1 |
| Pharm Classes | Prostacyclin Receptor Agonist [EPC],Prostacyclin Receptor Agonists [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
| Marketing Start Date | 2015-12-21 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA207947 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2015-12-21 |
| Ingredient | Strength |
|---|---|
| SELEXIPAG | 600 ug/1 |
| SPL SET ID: | a7a23b87-f892-4e2c-8e2e-ebf841220f90 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 66215-602 | UPTRAVI | Selexipag |
| 66215-604 | UPTRAVI | Selexipag |
| 66215-606 | UPTRAVI | Selexipag |
| 66215-608 | UPTRAVI | Selexipag |
| 66215-610 | UPTRAVI | Selexipag |
| 66215-612 | UPTRAVI | UPTRAVI |
| 66215-614 | UPTRAVI | UPTRAVI |
| 66215-616 | UPTRAVI | UPTRAVI |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() UPTRAVI 86829111 5074971 Live/Registered |
Actelion Pharmaceuticals Ltd 2015-11-23 |
![]() UPTRAVI 85348761 4087965 Live/Registered |
Actelion Pharmaceuticals Ltd 2011-06-17 |